Cambridge Investment Research Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 117,120 shares of RXRX stock, worth $535,238. This represents 0.0% of its overall portfolio holdings.
Number of Shares
117,120
Previous 87,984
33.12%
Holding current value
$535,238
Previous $595,000
4.2%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$159 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$148 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$111 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$79.1 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$67 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $825M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...